Irrational prescription of surfactant replacement therapy in neonatal respiratory distress

Nader Jahanmehr1,2, Reyhane Izadi1, Abbas Habibolahi3

  • 1Health Economics, Management and Policy Department, Virtual School of Medical Education & Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Plos One
|June 16, 2022
PubMed

Insights

Irrational surfactant prescriptions for neonates with respiratory distress in Iran were high, with 31.47% of cases showing errors in drug selection, dose, or timing. Interventions are needed to improve neonatal care and reduce these preventable medication errors.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Public Health

Background:

  • Respiratory distress is a primary cause of neonatal mortality.
  • Surfactant therapy has significantly improved outcomes for respiratory failure in neonates.
  • Increased surfactant prescription in Iran may be linked to irrational prescribing practices.

Purpose of the Study:

  • To determine the rate of irrational surfactant prescription for neonates with respiratory distress in Iran.
  • To analyze prescription patterns against established surfactant guidelines.

Main Methods:

  • A retrospective, cross-sectional descriptive study was conducted.
  • Data from 846 neonates receiving surfactant therapy in Iran in 2018 were analyzed.
  • Irrational prescribing was assessed based on drug selection, dose, and timing indices.

Main Results:

  • Irrational drug selection occurred in 14.30% of cases.
  • Irrational dosing was observed in 27.42% of cases.
  • A total of 31.47% of neonates received irrational surfactant prescriptions.

Conclusions:

  • The high rate of irrational surfactant prescriptions necessitates immediate attention from healthcare providers and policymakers.
  • Educational interventions and computer-based alerts are recommended to reduce prescription errors.
  • Improving surfactant prescribing practices is crucial for enhancing neonatal health outcomes.
Abstract

Related Concept Videos

Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
60.3K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
195
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.8K
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
315
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
424
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
345